arrow
J

John P. Leonard

University of Pennsylvania
H指数:85
被引数:3.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2-3 trial

维奈克拉联合剂量调整的EPOCH-R方案治疗新诊断的双打击淋巴瘤:来自ALLIANCE A051701开放标签、随机对照、II-III期试验的II期结果

2026-08-010
PRE
Impact of EBV Status and Histology on Patient Outcomes with Nivolumab-AVD vs BV-AVD in Advanced Classic Hodgkin Lymphoma (S1826)

EBV状态和组织学对纳武利尤单抗-AVD与博安拉塞-AVD在晚期经典霍奇金淋巴瘤中患者预后的影响(S1826)

2026-07-310
OA
Consensus Recommendations from the 2024 International Follicular Lymphoma Scientific Workshop

2024年国际滤泡性淋巴瘤科学研讨会共识建议

2025-12-050
OAAI
Nivolumab plus relatlimab for patients with relapsed or progressed B-cell malignancies in RELATIVITY-022

纳武利尤单抗联合罗特利珠单抗治疗复发或进展性B细胞恶性肿瘤的RELATIVITY-022研究

2025-03-050
OA
Vitamin D in patients with low tumor-burden indolent non- Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial
2024-12-011
OAAI
Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

自体造血细胞移植(auto-HCT)在无检测到的微小残留病(uMRD)的套细胞淋巴瘤(MCL)患者(pts)首次完全缓解(CR)中的获益不足:ECOG-ACRIN EA4151 III期随机试验的初步报告

BLOOD
IF23.1
2024-11-252
PRE
Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181

在≤70岁套细胞淋巴瘤患者强化一线化疗免疫治疗中添加或替代Acalabrutinib:ECOG-ACRIN EA4181三臂随机Ⅱ期协作组试验的结果

BLOOD
IF23.1
2024-11-051
PRE
MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naive Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA Analyses

MRD驱动的有限疗程Acalabrutinib联合Lenalidomide和Rituximab(ALR)或Obinutuzumab(ALO)治疗初治套细胞淋巴瘤患者的疗效:含MRD和cfDNA分析的II期试验结果

BLOOD
IF23.1
2024-11-051
PRE
Disrupting IL10 Signaling Overcomes Compound Copy Number Variation-Driven Clinical Resistance to CDK4/6 and BTK Inhibition in Mantle Cell Lymphoma

干扰IL10信号克服了复合拷贝数变异驱动的临床耐药性,对CDK4/6和BTK抑制在套细胞淋巴瘤中的作用

BLOOD
IF23.1
2024-11-050
PRE
Representation of Minorities in Therapeutic Clinical Trials- a 15-Year Review of Lymphoma Cooperative Group Studies (Alliance A152123)

少数民族在治疗性临床试验中的代表性——淋巴瘤协作组研究15年回顾 (Alliance A152123)

BLOOD
IF23.1
2024-11-050
PRE
Nivolumab plus AVD in Advanced-Stage Classic Hodgkin's Lymphoma
2024-10-172
PRE
CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema

KLKB1基因编辑在遗传性血管性水肿中的体内CRISPR-Cas9

2024-02-0145
PRE
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes

淋巴瘤结局流行病学队列研究: 设计、基线特征和早期结局

2024-01-136
PRE